The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IFx-Hu2.0 phase I first in human study for unresectable melanoma for an intralesional “in-situ vaccine” approach.
 
Joseph Markowitz
Stock and Other Ownership Interests - Aflac; Amdocs; Consolidated Edison; CVS; Intel
Honoraria - Springer
Consulting or Advisory Role - Newlink Genetics
Research Funding - Idera (Inst); Jackson Laboratory for Genomic Medicine (Inst); Merck (Inst); Microba (Inst); Morphogenesis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on development of Inhibitors for S100B (Inst); Pending patent on flow cytometry analysis system (Inst); Pending patent on the role of nitric oxide in melanoma. (Inst)
Other Relationship - Springer
 
Michael Shamblott
Employment - Morphogenesis
Leadership - Morphogenesis
Stock and Other Ownership Interests - Morphogenesis
Patents, Royalties, Other Intellectual Property - Morphogenesis
Travel, Accommodations, Expenses - Morphogenesis
 
Andrew Scott Brohl
Consulting or Advisory Role - Bayer; Deciphera
Expert Testimony - GlaxoSmithKline (I)
 
Amod Sarnaik
Honoraria - Medscape; MedStar Health; Physicans' Education Resource
Consulting or Advisory Role - B4CC; Defined Health; Gerson Lehrman Group; Guidepoint Global; Huron Consulting; Iovance Biotherapeutics; Istari; KeyQuest Health
Research Funding - Genentech (Inst); Iovance Biotherapeutics (Inst); Provectus (Inst)
Patents, Royalties, Other Intellectual Property - Compositions and methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy, filed March 20, 2014 U.S. Patent Application No. 61/955,970 and second Application No. 61/973,002 (Inst); Culture of Tumor-infiltrating lymphocytes from tumor digest, filed March 24, 2021 US Patent Application No. 17/279,327 (Inst); Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound, filed August 21, 2018 U.S. Patent Application No. 14/974,357; Rapid method for culture of tumor-infiltrating lymphocytes from core needle biopsies of solid tumors, filed January 2, 2018 U.S. Patent Application No. 62/612,915 (Inst); Tumor-infiltrating lymphocytes and stapled peptoid peptide hybrid peptidomimetics, filed October 11, 2018 U.S. Patent Application No. 16/157,174 (Inst)
Travel, Accommodations, Expenses - Iovance Biotherapeutics; Iovance Biotherapeutics
 
Zeynep Eroglu
Consulting or Advisory Role - Elsevier; Genentech/Roche; Natera; Novartis; OncoSec; Regeneron; Sun Pharma
Research Funding - Novartis (Inst); Pfizer (Inst)
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Genzyme; Immunocore; Incyte; Instil Bio; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Nektar; Novartis; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron
 
Pei-Ling Chen
Patents, Royalties, Other Intellectual Property - Pending patent unrelated to current abstract (Inst)
 
Deanryan B. De-Aquino
No Relationships to Disclose
 
Vernon K. Sondak
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck/Schering Plough; Novartis; Regeneron
Research Funding - Neogene Therapeutics (Inst); Turnstone Bio (Inst)
 
Ahmad A. Tarhini
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Clinigen Group; Eisai; Genentech/Roche; Instil Bio; Merck; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst)
 
Youngchul Kim
No Relationships to Disclose
 
Shari Pilon-Thomas
Consulting or Advisory Role - Seagen
Research Funding - Dyve Bioscience (Inst); Intellia Therapeutics (Inst); Iovance Biotherapeutics (Inst); Provectus Biopharmaceuticals (Inst); Turnstone Bio (Inst)
Patents, Royalties, Other Intellectual Property - Iovance Biotherapeutics (Inst); Moffitt Cancer Center; Provectus Biopharmaceuticals; Tuhura Biopharma (Inst)